Literature DB >> 14998485

Inactivation of Stat3 in tumor cells: releasing a brake on immune responses against cancer?

Ana M Gamero1, Howard A Young, Robert H Wiltrout.   

Abstract

A model of immune evasion mediated by tumors expressing constitutively activated Stat3 was recently proposed in Nature Medicine by Wang et al., suggesting opportunities for a new therapeutic approach for cancer.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14998485     DOI： 10.1016/s1535-6108(04)00028-5

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  17 in total

Review 1.  The emerging role of the LIV-1 subfamily of zinc transporters in breast cancer.

Authors:  Kathryn M Taylor; Helen E Morgan; Kathryn Smart; Normawati M Zahari; Sara Pumford; Ian O Ellis; John F R Robertson; Robert I Nicholson
Journal:  Mol Med       Date:  2007 Jul-Aug       Impact factor: 6.354

2.  Functional validation of genes implicated in lymphomagenesis: an in vivo selection assay using a Myc-induced B-cell tumor.

Authors:  Duonan Yu; Diana Cozma; Andrea Park; Andrei Thomas-Tikhonenko
Journal:  Ann N Y Acad Sci       Date:  2005-11       Impact factor: 5.691

3.  STAT3: a multifaceted oncogene.

Authors:  David E Levy; Giorgio Inghirami
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-26       Impact factor: 11.205

4.  Hepatitis C virus (HCV) constitutively activates STAT-3 via oxidative stress: role of STAT-3 in HCV replication.

Authors:  Gulam Waris; James Turkson; Tarek Hassanein; Aleem Siddiqui
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

5.  Inactivation of Myc in murine two-hit B lymphomas causes dormancy with elevated levels of interleukin 10 receptor and CD20: implications for adjuvant therapies.

Authors:  Duonan Yu; Michael Dews; Andrea Park; John W Tobias; Andrei Thomas-Tikhonenko
Journal:  Cancer Res       Date:  2005-06-15       Impact factor: 12.701

6.  Effects of cucurbitacins on cell morphology are associated with sensitization of renal carcinoma cells to TRAIL-induced apoptosis.

Authors:  Curtis J Henrich; Cheryl L Thomas; Alan D Brooks; Nancy Lynn Booth; Evan M Lowery; Richard J Pompei; James B McMahon; Thomas J Sayers
Journal:  Apoptosis       Date:  2012-01       Impact factor: 4.677

7.  Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3.

Authors:  Monika Kasprzycka; Michal Marzec; Xiaobin Liu; Qian Zhang; Mariusz A Wasik
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-09       Impact factor: 11.205

8.  Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles.

Authors:  Mian M K Shahzad; Lingegowda S Mangala; Hee Dong Han; Chunhua Lu; Justin Bottsford-Miller; Masato Nishimura; Edna M Mora; Jeong-Won Lee; Rebecca L Stone; Chad V Pecot; Duangmani Thanapprapasr; Ju-Won Roh; Puja Gaur; Maya P Nair; Yun-Yong Park; Nirupama Sabnis; Michael T Deavers; Ju-Seog Lee; Lee M Ellis; Gabriel Lopez-Berestein; Walter J McConathy; Laszlo Prokai; Andras G Lacko; Anil K Sood
Journal:  Neoplasia       Date:  2011-04       Impact factor: 5.715

9.  JSI-124 suppresses invasion and angiogenesis of glioblastoma cells in vitro.

Authors:  Guang Yuan; Shaofeng Yan; Hao Xue; Ping Zhang; Jintang Sun; Gang Li
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

Review 10.  Recent advances of sorafenib nanoformulations for cancer therapy: Smart nanosystem and combination therapy.

Authors:  Fangmin Chen; Yifan Fang; Xiang Chen; Rui Deng; Yongjie Zhang; Jingwei Shao
Journal:  Asian J Pharm Sci       Date:  2020-08-21       Impact factor: 6.598
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.